AKT1 and cholangiocarcinoma: The growth of CCA cells can be inhibited by hsa-miR-134-5p through the down-regulation of the Akt pathway, indicating that hsa-miR-134-5p has potential as a therapeutic target for cholangiocarcinoma (CCA) and could contribute to the development of effective treatment strategies [14].